View More View Less
  • 1 XV. ker. Onkológiai Gondozó, 1064, Budapest, Vörösmarty utca 31.
  • | 2 Onkoradiológiai Központ, Fővárosi Önkormányzat Uzsoki utcai Kórháza, Budapest
Restricted access

Absztrakt

Az előzetesen anthracyclinekkel és/vagy taxánokkal kezelt, de kiújult, progrediáló, áttétet képző emlőrák kezelése nemcsak az egészségügy számára jelent kihívást, de igen jelentős társadalmi kihatásai is vannak. Hivatalos protokollok hiányában a közlemény megkísérli összefoglalni azokat a bizonyítékokat, melyek segíthetnek a klinikai döntéshozatalban. Ebben a klinikai helyzetben 4 újabb gyógyszert fogadtak el: a capecitabint, a gemcitabint, az ixabepilont és a nanorészecske-albuminhoz kötött paclitaxelt. Az áttekintés összefoglalja ezen kívül az egyéb aktív hatóanyagokkal, mint a liposzomális doxorubicinnel, a taxánok cseréjével, a larotaxellal, a vinorelbinnel és a biológiai hatóanyagokkal történt vizsgálatok eredményeit.

  • 1. KS Albain SM Nag G Calderillo-Ruiz et al.2008 Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26 3950 3957.

    • Search Google Scholar
    • Export Citation
  • 2. JL Blum V Dieras PM Lo Russo et al.2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768.

    • Search Google Scholar
    • Export Citation
  • 3. JL Blum SE Jones AU Buzdar et al.1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493.

    • Search Google Scholar
    • Export Citation
  • 4. JL Blum MA Savin G Edelman et al.2004 Long term disease control in taxane refractory metastatic breast cancer treated with nab paclitaxel J Clin Oncol 22 Suppl S43.

    • Search Google Scholar
    • Export Citation
  • 5. JL Blum MA Savin G Edelman et al.2007 Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes Clin Breast Cancer 7 850 856.

    • Search Google Scholar
    • Export Citation
  • 6. C Bunnell L Vahdat L Schwartzberg et al.2008 Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer Clin Breast Cancer 8 234 241.

    • Search Google Scholar
    • Export Citation
  • 7. D Cameron M Casey M Press et al.2008 A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses Breast Cancer Res Treat 112 533 543.

    • Search Google Scholar
    • Export Citation
  • 8. AJ Chien MM Moasser 2008 Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired Semin Oncol 35 Suppl 2 S1 S14.

    • Search Google Scholar
    • Export Citation
  • 9. MA Cobleigh CL Vogel D Tripathy et al.1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648.

    • Search Google Scholar
    • Export Citation
  • 10. P Conte H Roché EA Perez et al.2009 Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies Cancer Res 69 Suppl 393s.

    • Search Google Scholar
    • Export Citation
  • 11. M De Laurentiis G Cancello D D'Agostino et al.2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials J Clin Oncol 26 44 53.

    • Search Google Scholar
    • Export Citation
  • 12. N Denduluri JA Low JJ Lee et al.2007 Phase II trial of ixabepilone, an epothilone B analogue, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 3421 3427.

    • Search Google Scholar
    • Export Citation
  • 13. S Dent H Messerschmith M Trudeau 2008 Gemcitabine in the management of metastatic breast cancer: A systematic review Breast Cancer Res Treat 108 319 331.

    • Search Google Scholar
    • Export Citation
  • 14. V Diéras S Limentani G Romieu et al.2008 Phase II multicenter study of larotaxel (XRP9881) a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy Ann Oncol 19 1255 1260.

    • Search Google Scholar
    • Export Citation
  • 15. LG Estévez N Batista P Sánchez-Rovira et al.2008 A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes Clin Breast Cancer 8 149 154.

    • Search Google Scholar
    • Export Citation
  • 16. WJ Gradishar S Tjulandin N Davidson et al.2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 7794 7803.

    • Search Google Scholar
    • Export Citation
  • 17. Hortobagyi GN , Perez EA, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials. Poster presented at ASCO Breast Cancer Symposium, 2008.

    • Search Google Scholar
    • Export Citation
  • 18. T Ishida T Kiba M Takeda et al.2009 Phase II study of capecitabine plus trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes Cancer Chemother Pharmacol 65 361 369.

    • Search Google Scholar
    • Export Citation
  • 19. V Kataja M Castiglione ESMO Guidelines Working Group 2008 Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 19 Suppl 2 ii11 ii13.

    • Search Google Scholar
    • Export Citation
  • 20. AM Keller RG Mennel VA Georgoulias et al.2004 Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer J Clin Oncol 22 3893 3901.

    • Search Google Scholar
    • Export Citation
  • 21. SF Li X Wang C Wang et al.2008 Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer [in Chinese] Zhonghua Zhong Liu Za Zhi 30 944 946.

    • Search Google Scholar
    • Export Citation
  • 22. RB Livingstone GK Ellis JR Gralow et al.1997 Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer J Clin Oncol 15 1395 1400.

    • Search Google Scholar
    • Export Citation
  • 23. DB Longley PG Johnston 2005 Molecular mechanisms of drug resistance J Pathol 205 275 292.

  • 24. JA Low SB Wedam JJ Lee et al.2005 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, in metastatic and locally advanced breast cancer J Clin Oncol 23 2726 2734.

    • Search Google Scholar
    • Export Citation
  • 25. M Martin A Ruiz M Munoz Spanish Breast Cancer Research Group (GEICAM) trial et al.2007 Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial Lancet Oncol 8 219 225.

    • Search Google Scholar
    • Export Citation
  • 26. EL Mayer HJ Burstein 2007 Chemotherapy for metastatic breast cancer Hematol Oncol Clin North Am 21 257 272.

  • 27. D Miles A Chan G Romieu et al.2008 Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO J Clin Oncol 26 Suppl 43s.

    • Search Google Scholar
    • Export Citation
  • 28. K Miller M Wang J Gralow et al.2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676.

    • Search Google Scholar
    • Export Citation
  • 29. KD Miller LI Chap FA Holmes et al.2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799.

    • Search Google Scholar
    • Export Citation
  • 30. A Moreno-Aspitia EA Perez 2009 Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends Clin Ther 31 1619 1640.

    • Search Google Scholar
    • Export Citation
  • 31. National Comprehensive Cancer Network. NCCN Practice guidelines in Oncology – v.2009: Breast Cancer. http://www.nccn.org/clinical.asp.

    • Search Google Scholar
    • Export Citation
  • 32. ME O'Brien N Wigler M Inbar CAELYX Breast Cancer Study Group et al.2004 Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440 449.

    • Search Google Scholar
    • Export Citation
  • 33. J O'Shaughnessy D Miles S Vukelja et al.2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results J Clin Oncol 20 2812 2823.

    • Search Google Scholar
    • Export Citation
  • 34. EA Perez G Lerzo X Pivot et al.2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 3407 3414.

    • Search Google Scholar
    • Export Citation
  • 35. NJ Robert V Dieras VJ Glaspy et al.2009 RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 27 Suppl 15s.

    • Search Google Scholar
    • Export Citation
  • 36. H Roché R Li J Ro et al.2009 Ixabepilone plus capecitabine improves progression-free survival in patients with metastatic breast cancer resistant to taxanes: A pooled analysis from two phase III studies Cancer Res 69 Suppl 160s.

    • Search Google Scholar
    • Export Citation
  • 37. H Roché L Yelle F Cognetti et al.2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 3415 3420.

    • Search Google Scholar
    • Export Citation
  • 38. HS Rugo H Roché E Thomas et al.2009 Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: A pooled analysis of patients from two large phase III clinical studies Cancer Res 69 Suppl 225s.

    • Search Google Scholar
    • Export Citation
  • 39. SEER Cancer Statistics Review, 1975–2006. http://seer.cancer.gov/csr/1975-2006.

  • 40. DJ Slamon B Leyland-Jones S Shak et al.2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792.

    • Search Google Scholar
    • Export Citation
  • 41. J Sparano A Makhson V Semiglazov et al.2009 Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: Results from a randomized phase III study Cancer Res 69 Suppl 82s.

    • Search Google Scholar
    • Export Citation
  • 42. O Tacca F Penault-Llorca C Abrial et al.2007 Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy Oncologist 12 636 643.

    • Search Google Scholar
    • Export Citation
  • 43. E Thomas J Tabernero M Fornier et al.2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399 3406.

    • Search Google Scholar
    • Export Citation
  • 44. ES Thomas HL Gomez RK Li et al.2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210 5217.

    • Search Google Scholar
    • Export Citation
  • 45. L Zelek S Barthier M Riofrio et al.2001 Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma Cancer 92 2267 2272.

    • Search Google Scholar
    • Export Citation

Magyar Onkológia
Language Hungarian
Size  
Year of
Foundation
1956
Publication
Programme
 
Volumes
per Year
 
Issues
per Year
 
Founder Magyar Onkológusok Társasága
Founder's
Address
H-1122 Budapest, Hungary Ráth György u. 7-9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0025-0244 (Print)
ISSN 2060-0399 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 8 0 0
May 2021 8 0 0
Jun 2021 12 0 0
Jul 2021 3 0 0
Aug 2021 7 0 0
Sep 2021 4 0 0
Oct 2021 0 0 0